During the last session, 4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s traded shares were 0.38 million, with the beta value of the company hitting 2.81. At the end of the trading day, the stock’s price was $3.06, reflecting an intraday gain of 5.15% or $0.15. The 52-week high for the FDMT share is $28.93, that puts it down -845.42 from that peak though still a striking 27.12% gain since the share price plummeted to a 52-week low of $2.23. The company’s market capitalization is $141.69M, and the average intraday trading volume over the past 10 days was 0.87 million shares, and the average trade volume was 841.94K shares over the past three months.
4D Molecular Therapeutics Inc (FDMT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.75. FDMT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.86.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
4D Molecular Therapeutics Inc (FDMT) registered a 5.15% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.15% in intraday trading to $3.06, hitting a weekly high. The stock’s 5-day price performance is 18.15%, and it has moved by -19.26% in 30 days. Based on these gigs, the overall price performance for the year is -88.56%. The short interest in 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is 5.06 million shares and it means that shorts have 6.76 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 49.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, FDMT is trading at a discount of -96.08% off the target high and -96.08% off the low.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
In the rating firms’ projections, revenue will increase 13,019.24% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 529.67k as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 525.83k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 28k and 5k respectively. In this case, analysts expect current quarter sales to grow by 1,791.68% and then jump by 10,416.60% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -9.89%. While earnings are projected to return -20.41% in 2025, the next five years will return -9.38% per annum.
FDMT Dividends
4D Molecular Therapeutics Inc is due to release its next quarterly earnings on 2025-Feb-27. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
4D Molecular Therapeutics Inc insiders own 3.89% of total outstanding shares while institutional holders control 103.14%, with the float percentage being 107.30%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 207.0 institutions own stock in it. As of 2024-06-30, the company held over 5.1 million shares (or 9.2221% of all shares), a total value of $107.01 million in shares.
The next largest institutional holding, with 4.9 million shares, is of BLACKROCK INC.’s that is approximately 8.8579% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $102.79 million.
Also, the Mutual Funds coming in first place with the largest holdings of 4D Molecular Therapeutics Inc (FDMT) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.54 shares. This amounts to just over 3.32 percent of the company’s overall shares, with a $4.7 million market value. The same data shows that the other fund manager holds slightly less at 1.23, or about 2.65% of the stock, which is worth about $3.75 million.
